Tag: Inc.

Poster-Neuroimmunology and disease models

Comparing Infection-Related Outcomes By Sex in Patients with Multiple Sclerosis and Matched Controls Using Administrative Claims Data

Background: Few population-level sex-based risk estimates of specific infections exist for US patients with multiple sclerosis (MS)....

Read More

Poster-Methods of Care

Floodlight MS: Using the Jobs-to-be-Done Framework to Identify Unmet Needs in Multiple Sclerosis Care to Support Digital Medical Device Development

Background: Multiple sclerosis (MS) is a chronic disease, and people living with MS (PLwMS) often experience symptoms across numerous...

Read More

Poster-Methods of Care

Floodlight MS: Utilizing Rapid Prototyping and Human Factors Studies to Develop a Digital Medical Device for Patient-Centric MS Care

Background: In multiple sclerosis (MS), subtle disease progression starts early despite initial presentation. Early neurologic damage can...

Read More

Poster-Disease-modifying Therapy

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...

Read More

Poster-Disease-modifying Therapy

Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the Asclepios I/II and Apolitos Studies

Background: Ofatumumab is a fully human anti-CD20 monoclonal antibody approved by the FDA for treatment of adults with relapsing multiple...

Read More

Poster-Disease-modifying Therapy

Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19

Background: Several integrated analyses have reported on the safety of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years...

Read More

Poster-Disease-modifying Therapy

Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World

Background: Siponimod was approved in the United States (US) in March 2019 for patients with relapsing forms of Multiple Sclerosis (MS)....

Read More

Poster-Disease-modifying Therapy

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study

Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...

Read More

Poster-Disease-modifying Therapy

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Background: A global pandemic of COVID-19 has resulted in over 78 million cases as of 23 December 2020. Risks of COVID-19 in people with...

Read More

Poster-Disease-modifying Therapy

Click-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)

Background: The efficacy and safety of cladribine tablets 3.5 mg/kg (cumulative dose over 2 years) have been shown in patients with...

Read More